ARCHIVES

Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 36 No. 3 | March 29, 2013

Download PDF Visit The Full Archive

Related Articles

Digital Microscope Blood Test Identifies Circulating Tumor Cells

February 24, 2012

Conversation With The Cancer Letter: Ronald DePinho Says Moon Shots Will Go On

January 18, 2013

Rall, FDA Chief On AACR Panel

April 27, 1979

TJU Wins NCI Renewal Of Kimmel Center Core Grant; 11 NY Centers Testing Spiral CT.

July 13, 2001

NCAB Approves Plan for National Black Leadership Initiative

October 16, 1987

European Agency Recommends Transfusions Over ESAs For Cancer Patients With Longer Life Expectancy.

June 27, 2008